FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898868611> ?p ?o ?g. }

• W2898868611 endingPage "S47" @default.
• W2898868611 startingPage "S47" @default.
• W2898868611 abstract "Abstract Background Bacteriophage therapy (BT) is a re-emerging strategy to treat antibiotic-resistant infections. Here, we describe our initial experience with intravenous (IV) and inhaled BT to treat life-threatening Staphylococcus aureus and Pseudomonas aeruginosa infections not responding to antibiotic therapy. Emergency Investigational New Drug application approvals (United States) or Special Access Scheme Category A notifications (Australia) and informed consent from the patients were obtained. Methods Patients were treated with AB-SA01 (3-phage product targeting S. aureus) and AB-PA01 (4-phage product targeting P. aeruginosa) produced in a Good Manufacturing Practice-certified facility. Pre- and posttreatment bacterial isolates were tested for phage susceptibility during BT. In all cases, concomitant antibiotics were continued. Safety was assessed clinically and using laboratory parameters with up to 90 days of follow-up. Samples to assess bacterial loads, bacteriophage kinetics in blood, and immune responses to phage were collected. Results As of April 2018, 8 patients were treated with BT; 5 with AB-SA01 (bacteremia, n = 4; endocarditis, n = 1) and 3 with AB-PA01 (lung infection, n = 3). Median duration of BT was 14 days and treated patients received over 90 IV doses of AB-SA01 (3 × 109 PFU/dose) and over 490 IV and nebulized doses of AB-PA01 (4 × 109 PFU/dose). BT was well tolerated, with no treatment-related adverse events. Clinical treatment success was documented in 75% of patients. Isolates collected during therapy showed ongoing susceptibility to the BT products with changes in sensitivity to the individual phage components observed in some cases. Bacteriophage kinetics revealed bloodstream clearance within a few hours after IV infusion, with an inferred initial bacteria:bacteriophage ratio of ~200 for the bacteremia patients. Conclusion BT was well tolerated as an adjunct to antibiotics, with several examples presented of microbiological eradication and improvement of objective clinical criteria. BT appears to be a safe adjunct to antibiotic therapy in life-threatening S. aureus and P. aeruginosa infections and is a promising candidate for controlled clinical trials. Disclosures S. Morales, AmpliPhi Biosciences: Employee, Salary. S. Lehman, AmpliPhi Biosciences: Employee, Salary. S. Branston, AmpliPhi Biosciences: Employee, Salary. A. Petrovic Fabijan, AmpliPhi Biosciences: Collaborator, Research support. C. L. Langlais Furr, AmpliPhi Biosciences: Employee, Salary. F. Rosas, AmpliPhi Biosciences: Employee, Salary. I. Bilinsky, AmpliPhi Biosciences: Employee and Shareholder, Salary. P. Grint, AmpliPhi Biosciences: Board Member, Employee and Shareholder, Salary. J. Iredell, AmpliPhi Biosciences: Collaborator, Research support." @default.
• W2898868611 created "2018-11-09" @default.
• W2898868611 creator A5001175222 @default.
• W2898868611 creator A5003556236 @default.
• W2898868611 creator A5005255843 @default.
• W2898868611 creator A5020040169 @default.
• W2898868611 creator A5021564452 @default.
• W2898868611 creator A5025858960 @default.
• W2898868611 creator A5028454923 @default.
• W2898868611 creator A5033839301 @default.
• W2898868611 creator A5048069105 @default.
• W2898868611 creator A5052262069 @default.
• W2898868611 creator A5052910151 @default.
• W2898868611 creator A5061082169 @default.
• W2898868611 creator A5079673027 @default.
• W2898868611 date "2018-11-01" @default.
• W2898868611 modified "2023-09-26" @default.
• W2898868611 title "1642. Safety and Efficacy of Bacteriophage Therapy: Analysis of Clinical Case Series Data" @default.
• W2898868611 doi "https://doi.org/10.1093/ofid/ofy209.112" @default.
• W2898868611 hasPublicationYear "2018" @default.
• W2898868611 type Work @default.
• W2898868611 sameAs 2898868611 @default.
• W2898868611 citedByCount "3" @default.
• W2898868611 countsByYear W28988686112019 @default.
• W2898868611 countsByYear W28988686112020 @default.
• W2898868611 countsByYear W28988686112023 @default.
• W2898868611 crossrefType "journal-article" @default.
• W2898868611 hasAuthorship W2898868611A5001175222 @default.
• W2898868611 hasAuthorship W2898868611A5003556236 @default.
• W2898868611 hasAuthorship W2898868611A5005255843 @default.
• W2898868611 hasAuthorship W2898868611A5020040169 @default.
• W2898868611 hasAuthorship W2898868611A5021564452 @default.
• W2898868611 hasAuthorship W2898868611A5025858960 @default.
• W2898868611 hasAuthorship W2898868611A5028454923 @default.
• W2898868611 hasAuthorship W2898868611A5033839301 @default.
• W2898868611 hasAuthorship W2898868611A5048069105 @default.
• W2898868611 hasAuthorship W2898868611A5052262069 @default.
• W2898868611 hasAuthorship W2898868611A5052910151 @default.
• W2898868611 hasAuthorship W2898868611A5061082169 @default.
• W2898868611 hasAuthorship W2898868611A5079673027 @default.
• W2898868611 hasBestOaLocation W28988686111 @default.
• W2898868611 hasConcept C104317684 @default.
• W2898868611 hasConcept C126322002 @default.
• W2898868611 hasConcept C185592680 @default.
• W2898868611 hasConcept C197934379 @default.
• W2898868611 hasConcept C2776441376 @default.
• W2898868611 hasConcept C2777637488 @default.
• W2898868611 hasConcept C2779256223 @default.
• W2898868611 hasConcept C2779443120 @default.
• W2898868611 hasConcept C501593827 @default.
• W2898868611 hasConcept C523546767 @default.
• W2898868611 hasConcept C54355233 @default.
• W2898868611 hasConcept C547475151 @default.
• W2898868611 hasConcept C55493867 @default.
• W2898868611 hasConcept C71924100 @default.
• W2898868611 hasConcept C86803240 @default.
• W2898868611 hasConcept C89423630 @default.
• W2898868611 hasConceptScore W2898868611C104317684 @default.
• W2898868611 hasConceptScore W2898868611C126322002 @default.
• W2898868611 hasConceptScore W2898868611C185592680 @default.
• W2898868611 hasConceptScore W2898868611C197934379 @default.
• W2898868611 hasConceptScore W2898868611C2776441376 @default.
• W2898868611 hasConceptScore W2898868611C2777637488 @default.
• W2898868611 hasConceptScore W2898868611C2779256223 @default.
• W2898868611 hasConceptScore W2898868611C2779443120 @default.
• W2898868611 hasConceptScore W2898868611C501593827 @default.
• W2898868611 hasConceptScore W2898868611C523546767 @default.
• W2898868611 hasConceptScore W2898868611C54355233 @default.
• W2898868611 hasConceptScore W2898868611C547475151 @default.
• W2898868611 hasConceptScore W2898868611C55493867 @default.
• W2898868611 hasConceptScore W2898868611C71924100 @default.
• W2898868611 hasConceptScore W2898868611C86803240 @default.
• W2898868611 hasConceptScore W2898868611C89423630 @default.
• W2898868611 hasIssue "suppl_1" @default.
• W2898868611 hasLocation W28988686111 @default.
• W2898868611 hasLocation W28988686112 @default.
• W2898868611 hasLocation W28988686113 @default.
• W2898868611 hasOpenAccess W2898868611 @default.
• W2898868611 hasPrimaryLocation W28988686111 @default.
• W2898868611 hasRelatedWork W2016394370 @default.
• W2898868611 hasRelatedWork W2090357739 @default.
• W2898868611 hasRelatedWork W2122792889 @default.
• W2898868611 hasRelatedWork W2572554549 @default.
• W2898868611 hasRelatedWork W2734626984 @default.
• W2898868611 hasRelatedWork W2790955358 @default.
• W2898868611 hasRelatedWork W2793753655 @default.
• W2898868611 hasRelatedWork W2970323266 @default.
• W2898868611 hasRelatedWork W4281552782 @default.
• W2898868611 hasRelatedWork W4289109240 @default.
• W2898868611 hasVolume "5" @default.
• W2898868611 isParatext "false" @default.
• W2898868611 isRetracted "false" @default.
• W2898868611 magId "2898868611" @default.
• W2898868611 workType "article" @default.